Partial registration of rights issue and last day for trading with BTA in Inhalation Sciences

The rights issue in Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) has been partially registered with the Swedish Companies Registration Office and paid subscribed shares (BTA) will thus be replaced by shares. The last day of trading in BTAs is June 14, 2023, and new shares are expected to be delivered to the shareholders' securities deposit/VP account on June 20, 2023.

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS.

ISAB has chosen to partially register the rights issue with the Swedish Companies Registration Office in order to be able to book out shares as soon as possible and get part of the issue proceeds paid out. The partial registration has been registered today, June 9, 2023, at the Swedish Companies Registration Office.

Information about paid subscribed shares

Ticker: ISAB BTA

ISIN code: SE0020053718

Last day of trading: June 14, 2023 

Advisors

Stockholm Corporate Finance AB acted as financial advisor and Fredersen Advokatbyrå AB as legal advisor. Hagberg & Aneborn Fondkommission AB was the issuing agent in connection with the rights issue.

About Stockholm Corporate Finance AB

Stockholm Corporate Finance is an independent privately owned financial advisor offering services within qualified advice on capital raising, ownership changes, mergers and acquisitions (M&A) to listed and private companies and their owners. Stockholm Corporate Finance is a securities company under the supervision of the Swedish Financial Supervisory Authority and is a member of the industry organization SwedSec Licensiering AB. For more information see: www.stockholmcorp.se

Important information

This press release does not constitute an offer to subscribe for, acquire or otherwise trade in shares, warrants, subscription rights, BTAs or other securities in Inhalation Sciences Sweden AB (publ) and investors should not subscribe for or acquire any securities other than on the basis of the information contained in the information memorandum published on April 21, 2023. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.

The information in this press release may be announced, published, copied, or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell new shares, warrants, BTAs, subscription rights or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require additional prospectuses, registration, or other measures than under Swedish law. The Information Memorandum, the application form and other documents related to the Rights Issue may not be distributed in or to any country where such distribution or the Rights Issue requires measures as stated in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws.

None of the shares, warrants, subscription rights, BTAs or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs or current expectations and goals regarding the Company's future operations, financial condition, liquidity, results of operations, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and can be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might" or, in each case, their negative, or similar, expressions. The forward-looking statements in this press release are based on various assumptions, many of which are in turn based on additional assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, actual results or performance could differ materially from those reflected in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from error and does not accept any responsibility for the future accuracy of the views expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as of the date hereof and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.

For further information, please contact:
Manoush Masarrat, CEO
Tel: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se  

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for inhalation research. The Company's patented laboratory instrument, PreciseInhale®, offers researchers the opportunity to characterize, with very high precision, how aerosols and small particles affect our lungs and thus our health when inhaled.